Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Roche Media News
Get the latest updates from Roche Media News directly as they happen.
Follow now 321 followers
Latest posts
Last updated 8 days ago
Changes to the Roche Enlarged Corporate Executive Committee
8 days ago
Basel, 30 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
15 days ago
Positive phase I/II data presented at the 2025 International Society on Thrombosis...
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
18 days ago
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival...
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
22 days ago
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
23 days ago
After a thorough clinical review, the benefit-risk for the use of Elevidys...
Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)
about 1 month ago
Simplified storage and administration of new tablet formulation may provide greater freedom...
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
about 1 month ago
46% reduction in the risk of disease progression or death, and 27%...
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
about 1 month ago
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than...
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
about 1 month ago
Patients on fenebrutinib had low relapse rates with data showing no active...
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
about 2 months ago
Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in...
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology
about 2 months ago
The strategic collaboration with Broad Clinical Labs will explore and develop applications...
New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients
about 2 months ago
Updated data from the pivotal phase III STARGLO study continue to demonstrate...